These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 19480923)

  • 1. Chapter 12. The use of receptor homology modeling to facilitate the design of selective chemokine receptor antagonists.
    Carter PH; Tebben AJ
    Methods Enzymol; 2009; 461():249-79. PubMed ID: 19480923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5.
    Andrews G; Jones C; Wreggett KA
    Mol Pharmacol; 2008 Mar; 73(3):855-67. PubMed ID: 18042736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chapter 8. Activation mechanisms of chemokine receptors.
    Jensen PC; Rosenkilde MM
    Methods Enzymol; 2009; 461():171-90. PubMed ID: 19480919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular modeling and site-directed mutagenesis of CCR5 reveal residues critical for chemokine binding and signal transduction.
    Zhou N; Luo Z; Hall JW; Luo J; Han X; Huang Z
    Eur J Immunol; 2000 Jan; 30(1):164-73. PubMed ID: 10602038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elucidation of binding sites of dual antagonists in the human chemokine receptors CCR2 and CCR5.
    Hall SE; Mao A; Nicolaidou V; Finelli M; Wise EL; Nedjai B; Kanjanapangka J; Harirchian P; Chen D; Selchau V; Ribeiro S; Schyler S; Pease JE; Horuk R; Vaidehi N
    Mol Pharmacol; 2009 Jun; 75(6):1325-36. PubMed ID: 19297521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure modeling of the chemokine receptor CCR5: implications for ligand binding and selectivity.
    Paterlini MG
    Biophys J; 2002 Dec; 83(6):3012-31. PubMed ID: 12496074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New therapeutics that modulate chemokine networks.
    Schwarz MK; Wells TN
    Nat Rev Drug Discov; 2002 May; 1(5):347-58. PubMed ID: 12120410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural Analysis of Chemokine Receptor-Ligand Interactions.
    Arimont M; Sun SL; Leurs R; Smit M; de Esch IJP; de Graaf C
    J Med Chem; 2017 Jun; 60(12):4735-4779. PubMed ID: 28165741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical potential of chemokine receptor antagonists.
    Ribeiro S; Horuk R
    Pharmacol Ther; 2005 Jul; 107(1):44-58. PubMed ID: 15894378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach.
    Berkhout TA; Blaney FE; Bridges AM; Cooper DG; Forbes IT; Gribble AD; Groot PH; Hardy A; Ife RJ; Kaur R; Moores KE; Shillito H; Willetts J; Witherington J
    J Med Chem; 2003 Sep; 46(19):4070-86. PubMed ID: 12954060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemokine receptor antagonists: Part 1.
    Pease JE; Horuk R
    Expert Opin Ther Pat; 2009 Jan; 19(1):39-58. PubMed ID: 19441897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemokine-binding specificity of soluble chemokine-receptor analogues: identification of interacting elements by chimera complementation.
    Datta-Mannan A; Stone MJ
    Biochemistry; 2004 Nov; 43(46):14602-11. PubMed ID: 15544331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The activation mechanism of chemokine receptor CCR5 involves common structural changes but a different network of interhelical interactions relative to rhodopsin.
    Springael JY; de Poorter C; Deupi X; Van Durme J; Pardo L; Parmentier M
    Cell Signal; 2007 Jul; 19(7):1446-56. PubMed ID: 17320349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for negative binding cooperativity within CCR5-CCR2b heterodimers.
    El-Asmar L; Springael JY; Ballet S; Andrieu EU; Vassart G; Parmentier M
    Mol Pharmacol; 2005 Feb; 67(2):460-9. PubMed ID: 15509716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding of 2-aryl-4-(piperidin-1-yl)butanamines and 1,3,4-trisubstituted pyrrolidines to human CCR5: a molecular modeling-guided mutagenesis study of the binding pocket.
    Castonguay LA; Weng Y; Adolfsen W; Di Salvo J; Kilburn R; Caldwell CG; Daugherty BL; Finke PE; Hale JJ; Lynch CL; Mills SG; MacCoss M; Springer MS; DeMartino JA
    Biochemistry; 2003 Feb; 42(6):1544-50. PubMed ID: 12578367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanding GPCR homology model binding sites via a balloon potential: A molecular dynamics refinement approach.
    Kimura SR; Tebben AJ; Langley DR
    Proteins; 2008 Jun; 71(4):1919-29. PubMed ID: 18175323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analyzing ligand and small molecule binding activity of solubilized GPCRs using biosensor technology.
    Navratilova I; Dioszegi M; Myszka DG
    Anal Biochem; 2006 Aug; 355(1):132-9. PubMed ID: 16762304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene conversion between mammalian CCR2 and CCR5 chemokine receptor genes: a potential mechanism for receptor dimerization.
    Vàzquez-Salat N; Yuhki N; Beck T; O'Brien SJ; Murphy WJ
    Genomics; 2007 Aug; 90(2):213-24. PubMed ID: 17544254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of molecular modeling, site-directed mutagenesis, and SAR studies to delineate the binding site of pyridopyrimidine antagonists on the human CCK1 receptor.
    Martín-Martínez M; Marty A; Jourdan M; Escrieut C; Archer E; González-Muñiz R; García-López MT; Maigret B; Herranz R; Fourmy D
    J Med Chem; 2005 Jul; 48(15):4842-50. PubMed ID: 16033264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A chemokine receptor antagonist inhibits experimental breast tumor growth.
    Robinson SC; Scott KA; Wilson JL; Thompson RG; Proudfoot AE; Balkwill FR
    Cancer Res; 2003 Dec; 63(23):8360-5. PubMed ID: 14678997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.